

Special Issue

Vaccine-Induced Immune Thrombotic Thrombocytopenia

Message from the Guest Editors

We are releasing a Special Issue of *Vaccines* on vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare adverse event following immunization (AEFI) associated with COVID-19 vaccines. We aim to deepen our understanding of VITT and welcome submissions on mechanisms, clinical manifestations, diagnostic criteria, and management strategies. The Special Issue is open for submissions until 30 September 2024. Accepted manuscripts will contribute to our understanding of VITT, benefiting healthcare professionals, researchers, and policymakers in making informed decisions. Thank you for your contributions.

Guest Editors

Dr. Doris F. Oberle

Department of Safety of Biomedicines and Diagnostics, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany

Dr. Linda Schönborn

Institute for Transfusion Medicine, University Hospital Greifswald, 17487 Greifswald, Germany

Deadline for manuscript submissions

closed (31 March 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/192822

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).